Page 97 - MemoriaBBN-Eng

www.ciber-bbn.es

• d. d, J. o, s. d, C. d, l. m. l. Grating couplers inte-
Most relevant uvAlsmondAnteomínGuezAnd eChuGA
grated on Mach-Zehnder interferometric biosensors operating in the visible range
scientific IEEE PHOTONICS JOURNAL. 2013;5(2):3700108/1-8.

articles
• de JuAn-FrAnCo e, rodríGuez-FrAde Jm, mellAdo m, leChuGA lm.. Implementation of an
SPR immunosensor for the simultaneous detection of the 22K and 20K hGH isoforms

in human serum samplesTalanta. 2013;11:268-75.

• e. de JuAn-FrAnCo, A. CAruz, J.r. PedrAJAs, And l. m. leChuGA. Site-directed antibody
immobilization using a protein A-gold binding domain fusion protein for enhanced

SPR immunosensingANALYST . 2013;138(7):2023-2031.

• B. veGA; A. CAlle; A. sánChez; l. m leChuGA; G. Armelles; J. m. rodríGuez FrAde And m.
m. Real-time detection of the chemokine CXCL12 in urine samples by surface
ellAdo
plasmon resonanceTalanta. 2013;15(109):209-15.

• duvAl, dAPhne; leChuGA, lAurA m. 2012 Breakthroughs in Lab-on-a-chip & Optical bio-
sensors IEEE PHOTONICS JOURNAL. 2013;5(2):00906-00906.

• In the research line of integrated silicon nanophotonic biosensors, important
Highlights
milestones have been reached for the implementation of a sensitive, affordable,
hand-held and portable point-of-care device. The ultrasensitive limit of detec-

tion of this technology at the pM-fM level is far beyond the state-of-the-art. A

technological transfer plan has been initiated in 2013. Several new projects
have been granted in 2013 related to this research line: the national project

EPISENS (TEC2012-34280) “Lab-on-a-chip integration of biophotonic devices
to study gene expression alterations in cellular pathways” and two EU projects:

BRAAVOO (FP7-OCEAN-201-614010) “Biosensors, Reporters and Algal Autono-

mous Vessels for Ocean Operation” and POCKET (FP7-ICT-2013-10-610389)
“Development of a low-cost point-of-care test for Tuberculosis detection”.

• The utility of our nanophotonic biosensing techniques for real bioanalytical ap-

plications has been successfully demonstrated. We are focusing in the point-

of-care detection of diseases as for example Malaria (collaboration with FIND
diagnostics Foundation) or Tuberculosis (POCKET EU project), early detection

of several types of cancer (as colorectal cancer), dry eye disease (INNPACTO

national project); early detection of liver complications (CIBER internal pro-
ject); novel sensor for in-situ doping control with a high level of sensitivity and

accuracy; monitoring of celiac or allergic patients directly in their human fluids,

among others (most of them in collaboration with private companies). In the
environmental field, we are focusing in the early detection of toxic pollutants as

pesticides, antibiotics or alga toxins (BRAAVOO EU project).

• We have successfully initiated in 2013 a new fundamental research line in Mo-
13
lecular Biology using our nanobiosesing technology for the deciphering of al- 20
terations in the cellular pathways, including alternative splicing of RNA, and T
OR
epigenetics modifications (DNA metilation or microRNA release).
P
RE
2013 indicators to be noted: 11 international publications, 3 granted patents, 22 L
A
invited contributions to conferences and courses.
NU
N
A
N /
B
-B
R
BE
CI

97